Evaluation of the prognostic value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy (DSAC)
| Autor: | G. Fountzilas, Helen Gogas, C. Vamvouka, A. Margariti, A. Asimaki, D. Tziortziotis, D.V. Skarlos, K. Pavlaki, T. Toliou, V. Kiriakou, E. Kirkou |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Adjuvant chemotherapy business.industry Incidence (epidemiology) medicine.disease law.invention chemistry.chemical_compound Breast cancer Randomized controlled trial Paclitaxel chemistry law Internal medicine medicine Immunohistochemistry business Epirubicin medicine.drug Hormone |
| Zdroj: | Journal of Clinical Oncology. 23:627-627 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.627 |
| Popis: | 627 Background: To assess the prognostic significance of positive p53 and Bcl-2 expression in high-risk patients with breast cancer treated with DSAC. Methods: From 11–6-1997 until 2–11-2000, 595 eligible patients were randomized to receive DSAC with epirubicin and intensified CMF with or without paclitaxel. In 397 patients, p53 and Bcl-2 were assessed centrally by immunohistochemistry (IHC) using NeXes automated system (Ventana). Both P53 and Bcl-2 data were available in 375 patients. Results: p53 and Bcl-2 expression was detected in 100 (25.5%) and 194 (49%) patients, respectively. The absence of Bcl-2 expression was significantly higher in patients with p53 expression (p=0.04). Incidence of p53 immuno-positivity was significantly higher in patients with grade III tumors (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|